文献速递造血干细胞移植与细胞治疗淋巴瘤

PTPN2缺失增强CAR-T效应功能并在非人灵长类模型中增加中枢神经系统浸润与毒性

PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.
PubMed 文献 · Blood Adv · 2026-09-02

该研究在非人灵长类模型中评估PTPN2敲除的人CD19/CD20 CAR-T细胞,发现其体外细胞因子产生、增殖、细胞毒性和信号传导增强,体内扩增和B细胞清除呈剂量依赖性优于野生型,但伴随更严重神经毒性/ICANS,与中枢神经系统浸润增加相关。

要点

  • PTPN2敲除增强CAR-T体外效应功能与低CD19白血病细胞清除。
  • 非人灵长类模型中PTPN2敲除CAR-T体内扩增和B细胞清除优于野生型。
  • PTPN2敲除CAR-T伴随更严重神经毒性/ICANS,与CNS浸润增加相关。

核心结论

  • PTPN2敲除可增强CAR-T的靶向功能,但增加神经毒性/ICANS风险,需严格临床前评估。

研究设计与样本

  • 研究采用人CD19 CAR-T体外功能实验及非人灵长类CD20/B细胞靶向CAR-T剂量递增体内研究。

主要发现

  • PTPN2敲除人CD19 CAR-T的细胞因子产生、增殖、细胞毒性、TCR和CAR功能性亲和力及信号传导增强。
  • PTPN2敲除CAR-T在体外更有效清除低CD19表达的白血病细胞。
  • 非人灵长类模型中PTPN2敲除CAR-T的体内扩增和B细胞清除呈剂量依赖性优于野生型。
  • PTPN2敲除CAR-T扩增与更严重毒性相关,尤其是神经毒性/ICANS,由CNS浸润增强驱动。
  • 转录谱显示以效应和增殖特征为主,细胞毒性CNS浸润CD8+ PTPN2敲除CAR-T参与ICANS发病。

临床怎么用

  • PTPN2敲除是增强CAR-T效力的潜在策略,但需警惕并监测神经毒性/ICANS。

局限性

  • 研究为非人灵长类模型,尚未在患者中验证疗效与毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell targeting CAR-T cells (CAR-T) therapies achieve high remission rates, yet durable responses occur in fewer than 40% of patients. Deletion of negative T-cell regulators such as PTPN2, a key inhibitor of TCR and cytokine signaling, represents a promising strategy to enhance CAR-T efficacy. While transfer of PTPN2-knockout (KO) T cells has demonstrated antitumor benefits in murine models, their impact on human-derived CAR-Ts and, importantly, the associated in vivo efficacy and toxicity remain unclear. Here, we demonstrate that PTPN2-KO human CD19 CAR-Ts exhibit enhanced cytokine production, proliferation, cytotoxicity, TCR and CAR functional avidity and signaling, which together lead to superior in vitro elimination of leukemic cells with low CD19 expression. In an in vivo dose-escalation study in a non-human primate (NHP) model of CD20/B-cell-targeting CAR-T therapy, we demonstrated that PTPN2-KO CAR-Ts exhibited superior in vivo expansion and B-cell depletion in a dose-dependent manner than PTPN2-WT CAR-Ts. PTPN2-KO CAR-T expansion was associated with increased toxicities, particularly neurotoxicity/ICANS, compared to WT CAR-Ts, driven by enhanced CNS-infiltration. Transcriptional profiling revealed a dominant effector and proliferative signature, with cytotoxic CNS-infiltrating CD8+ PTPN2-KO CAR-Ts implicated in ICANS pathogenesis. This study details the comprehensive evaluation of PTPN2-KO CAR-Ts in an immunocompetent primate model, demonstrating their enhanced on-target functionality, while highlighting increased toxicity risks, underscoring the value of rigorous preclinical assessment of potent genetic modifications in CAR-T therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Alvarez-Calderon F, Fleming RA, Winschel MB, et al. PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model. Blood Adv. 2026. PMID: 42685352. doi:10.1182/bloodadvances.2026019744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。